BioKnow

Top Pharma Companies by 2024 Pipeline Size ?? Check out the latest data from the Citeline Pharma R&D Review 2024, showcasing the top global pharmaceutical companies ranked by the number of drug candidates in their pipeline. ?? ?? Roche leads the pack with 218 drug candidates, followed closely by Pfizer at 205. ?? AstraZeneca, Lilly, and Bristol Myers Squibb round out the top five, all with impressive R&D pipelines. ?? Companies from the USA, Switzerland, France, UK, China, and Japan are all represented, highlighting the global nature of pharmaceutical innovation. Key insights: The USA dominates the list, with several companies leading innovation. Switzerland’s Roche holds the top position, demonstrating its continued investment in cutting-edge research. AstraZeneca and GSK represent the UK, showcasing the country's strong role in pharma R&D. China's presence with Hengrui signals growing innovation power in Asia. ?? The future of healthcare innovation looks brighter than ever as these companies work tirelessly on new treatments for various diseases. #biotech #biopharma #pharmaceuticals

??????????'?? ?????????????? ??????????????????/??.??. ?????????????????? ???????????????? ?? 115 companies focused on oncology, I&I and obesity with a mixture of both private and public companies. These collaborations enable rapid advancement in drug development, clinical trials, and market access, addressing both global and local healthcare challenges. The growing interest from international investors and the Chinese government’s supportive policies are further fueling the biotech sector’s expansion, positioning China as an emerging key player in global biotech research. Image Credit/Source: Dennis Gong #biotech #biopharma #immunology #oncology

Global Prophylactic Vaccines Market Map ?? Merck, GSK and Pfizer dominate this space with the Gardasil, Shingrix and Prevnar franchises leading the way respectively. ? These three also have some exciting drugs that are newly launched or late-stage pipeline including: - Merck’s Capvaxive for Pneumococcal Diseases – launched last year with strong growth forecasted this year - GSK’s 5-in-1 meningococcal ABCWY?vaccine Penmenvy, which was just approved on February 15th - Pfizer’s Phase 3 drug PF-07307405, as exciting vaccine for Lyme’s Disease which has FAST TRACK designation Thanks again to PharmaSights/Alexander Bonebakker for collaborating here. #biotech #biopharma #vaccines #immunoloft

?????? ?????????????? ?????????????????? ?? 85 companies targeting Amyotrophic Lateral Sclerosis with 4 marketed therapies/products. ???????????????? ??????????????????/????????????????: 1. Riluzole (Rilutek) - The first drug approved for ALS, works by inhibiting glutamate release, which is thought to slow down the degenerative process. 2. Edaravone (Radicava) - A free radical scavenger that has shown to reduce oxidative stress, a major factor in ALS progression. 3. AMX0035 - A combination therapy involving two drugs (sodium phenylbutyrate and taurursodiol) aimed at reducing cell death by targeting cellular stress pathways. 4. Tofersen - A targeted gene therapy designed for patients with SOD1 mutations, aiming to reduce toxic proteins that contribute to ALS progression. ?????????? ?????????????????? ?????? ?????????????????????? ????????????????????: Gene Therapy: Companies are exploring the use of gene editing (e.g., CRISPR) and RNA-based therapies (e.g., antisense oligonucleotides) to treat genetic mutations causing ALS. Cell Therapies: A few companies are focused on stem cell-based therapies to replace damaged motor neurons. Neuroprotective Agents: Companies are targeting neurodegenerative mechanisms, including oxidative stress, mitochondrial dysfunction, and protein aggregation. Immunotherapy: Research is being done to modulate the immune system, aiming to reduce neuroinflammation, a major contributor to ALS progression. Small Molecules: Some companies are developing small molecule drugs to modulate ALS-associated proteins like TDP-43 and C9ORF72. #neurology #biotech #biopharma #als

FREE Biotech Newsletter: YOUR gateway to the latest breakthroughs... Here’s the proof: - 90% of our subscribers report feeling more informed about biotech developments. - Join a community of over 10,000 biotech enthusiasts who share insights and updates weekly! Join here: https://lnkd.in/decTJM6Q ?? Stay at the Forefront with critical updates and insider insights. ?? Don’t Miss a Beat in the rapidly evolving world of biotech! ?? Click Here Join Now and transform your understanding of biotech today! #Biotech #Biopharma #Pharmaceuticals

Pharma Companies Dominating R&D Investment??? R&D investment plays a crucial role in driving small to large pharmaceutical innovation. Typically, pharmaceutical companies dedicate 19–25% of their revenue to R&D to support clinical trials, drug discoveries, and IP portfolios. In 2024, the average R&D investment across leading pharmaceutical companies was approximately 21%. Here are the pharma companies with the highest R&D investment: 1. Roche – 28.73% 2. Merck – 27.94% 3. AstraZeneca – 25.12% 4. Eli Lilly and Company – 24.40% 5. GSK – 22.72% 6. AbbVie – 20.40% 7. Novartis – 19.92% 8. Johnson & Johnson – 19.48% 9. Bristol Myers Squibb – 19.25% 10. Amgen – 18.62% 11. Sanofi – 18.00% 12. Pfizer – 16.94% 13. Novo Nordisk – 16.55% Credit/Source: Joanna Sadowska, PhD, EMBA. Amazing as always :) #pharmaceuticals #biotech #biopharma

Biopharma M&A Heats Up: Top 20 Deals by Valuation (2023-2025 YTD) ???? The biopharma industry continues its M&A momentum, with oncology, CNS, and I&I emerging as the most sought-after therapeutic areas. ?? Pfizer's $41B acquisition of Seagen leads the pack, strengthening its ADC oncology portfolio. ?? J&J and BMS bet big on CNS, targeting schizophrenia and depression treatments. ?? AbbVie & Roche prioritize oncology and inflammation, doubling down on ADCs and TL1A inhibitors. ?? Rare diseases & metabolic disorders gain traction, with Biogen (Reata) and Eli Lilly (Scorpion, Versanis) making strategic plays. Notably, premium valuations remain high—AbbVie's $9B ImmunoGen deal came at a staggering 95% premium, signaling fierce competition for breakthrough assets. As biopharma continues to navigate R&D challenges, patent cliffs, and market shifts, M&A is proving to be a critical growth lever. What trends stand out to you? Credit/Source: Bloomberg & Deutsche Bank #biotech #biopharma #pharmaceuticals #neurology

Visualizing RNA in Live Cells with CRISPR! Fascinating video captures researchers tracking single RNA molecules inside living cell - without modifying them! This breakthrough, powered by smLiveFISH, uses the CRISPR–Csm system to achieve high-resolution, real-time imaging of native RNA. What this video shows: ?? Fluorescently labeled RNA molecules moving dynamically inside a live cell ?? NOTCH2 mRNA anchoring to the ER for cotranslational translocation ?? MAP1B mRNA undergoing directional transport toward the cell periphery Why this matters: ? No need to alter RNA sequences—true native RNA tracking ? Works across multiple cell types, including primary cells ? Unlocks new insights into gene expression, RNA transport, and disease mechanisms This innovation, led by Jennifer Doudna and colleagues, is set to transform RNA biology and therapeutic research. Congratulations everyone. What are your thoughts on CRISPR-powered RNA imaging? #genetherapy?#biotech #biopharma #crispr

Calling all BioKnow'ers! Mark your calendars for the second edition of the London Biotechnology Show from 18-19 June 2025 at ExCeL London. This premier global event will spotlight groundbreaking technologies that are shaping the future of medical and healthcare sectors. Seize the opportunity to be part of this exclusive gathering, where you can connect with industry leaders, build valuable relationships, and contribute to the growth of biotechnology. Join the UK's premier biotechnology event for two days of innovation, networking and opportunity. Register today at?https://lnkd.in/gHcAfZjT #lbs #lbs25 #londonbiotechnologyshow #biotechnology #bioinformatics #medtech #innovation #lifesciences #healthcare #pharmaceutical #biomedicalengineering #tissueengineering #biotechconference #biotechevent #biotechexpo #redbiotechnology #excellondon #londonbiotech

Top 25 Biotech Companies in Europe (2025) ??? Europe’s biotech sector is thriving! A new ranking of the top 25 biotech companies in Europe (by market cap as of January 27, 2025). ?? Leading the pack is Belgium-based argenx ($39B), followed closely by Germany’s BioNTech ($28.3B) and Denmark’s Genmab ($13.9B). These companies are driving breakthroughs in immunotherapy, oncology, and mRNA technology. ?? Other notable names include Ascendis Pharma ($7.8B), CureVac ($7.8B), and Moonlake ($2.9B)—each making waves in gene therapy, mRNA vaccines, and immunology. ?? The diversity of companies across the UK, France, Switzerland, and Scandinavia shows Europe’s strong biotech ecosystem, spanning oncology, rare diseases, gene editing, and diagnostics. Source: Flot.bio - follow them for superb insights and a great podcast too. #biotech #biopharma #pharma